Search Results

DuChemBio Completes Supply Chain for Prostate Cancer Radiopharmaceutical

DuChemBio, a Korean radiopharmaceutical company, announced on August 4 that it has completed the supply chain for ProstaSeek (active ingredient: 18F-plotupolastat), a radiopharmaceutical for prostate cancer diagnosis, in the Yeongnam and Honam regions. The drug targets prostate-specific membrane antigen (PSMA), and all tertiary general hospitals in both regions that perform PET-CT scans and provide prostate cancer diagnosis and treatment have been included in its supply scope. According to data from the National Cancer Registry of the Korean Ministry of Health and Welfare, new prostate cancer cases reached 22,640 in 2023, accounting for 7.8% of all cancer cases and ranking sixth in male cancer incidence; with the increasing adoption of PSMA-targeted therapy, the demand for precise diagnosis before prostate cancer treatment is also growing rapidly.

2026-08-04

Ratio Therapeutics Completes $70 Million Series C Financing to Advance Clinical Development of Ac-225 Targeted Radiopharmaceuticals

Ratio Therapeutics, Inc., a U.S. clinical-stage pharmaceutical company, recently announced the completion of a $70 million Series C financing round. The company stated that following this round, its cumulative total financing has exceeded $240 million. According to the announcement, this round saw participation from existing investors Duquesne Family Office and Bristol Myers Squibb, while also bringing in new investors such as Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. Ratio Therapeutics stated that the proceeds will be used to advance the clinical development of its targeted radiotherapeutic product pipeline and expand manufacturing infrastructure. The company plans to continue advancing the ATLAS study, which is evaluating its lead radiotherapeutic agent [Ac-2...

2026-08-03

Bolivia Advances Legislative Process for Peaceful Nuclear Technology Applications

EL ALTO, Bolivia, July 29 - The Bolivian Nuclear Energy Agency (ABEN) recently held working exchanges with relevant committees of the Plurinational Legislative Assembly to discuss the reactivation of related legislative agendas, focusing on the continued advancement of Bolivia's nuclear energy program and peaceful nuclear technology application projects. René Soria Sausedo, Executive Director of ABEN, stated that as the primary operating entity of Bolivia's nuclear program, ABEN bears the responsibility of driving the implementation of peaceful nuclear technology application projects. These efforts require modern legal instruments to define institutional mandates, technical standards, and the fundamental legal framework for project development. The parliamentary delegation, led by the President of the International Policy and Migration Protection Committee, visited ABEN facilities...

2026-08-03

Thor Medical Launches Commercial Production of Lead-212 at AlphaOne Facility

Thor Medical ASA announced on July 31 that commercial production has commenced at its industrial-scale AlphaOne production facility located in the Herøya industrial park. The facility will produce lead-212 (Pb-212) and its precursors thorium-228 (Th-228) and radium-224 (Ra-224) to support demand related to radiopharmaceuticals and targeted cancer radiotherapy. According to the company, Thor Medical has signed supply agreements with multiple types of customers across the radiopharmaceutical value chain, including startup biotechnology companies, contract development and manufacturing organizations (CDMOs), and global pharmaceutical companies. The company expects the AlphaOne facility to deliver its first products to customers in August 2026. AlphaOn...

2026-08-01

Kazakhstan advances the use of radiation technology for agricultural preservation and advanced wastewater treatment.

Sayabek Sakhiyev, Director of the Institute of Nuclear Physics of Kazakhstan, recently stated that radiation technology holds promise for helping Kazakhstan reduce post-harvest losses, extend the shelf life of agricultural products, and facilitate advance

2026-07-27